Home
ANAB
ANAB News

Latest AnaptysBio Inc. (ANAB) News on April 2, 2025

AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

Zacks

8 days ago

AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

MT Newswires

9 days ago

AnaptysBio Approves $75 Million Buyback Plan; Shares Rise

Anaptys Announces Stock Repurchase Plan

GlobeNewswire

9 days ago

Anaptys Announces Stock Repurchase Plan

Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks

TipRanks

17 days ago

Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

Zacks

a month ago

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

a month ago

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Anaptys Announces Participation in March Investor Conferences

GlobeNewswire

a month ago

Anaptys Announces Participation in March Investor Conferences

Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data

TipRanks

2 months ago

Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

Zacks

2 months ago

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

Zacks

2 months ago

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial

Clinical Trials Arena

2 months ago

AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial

AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment

Investor's Business Daily

2 months ago

AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment

MT Newswires

2 months ago

AnaptysBio's Rheumatorid Arthritis Drug Meets Primary Endpoint in Phase 2 Trial; Shares Rise

MT Newswires

2 months ago

Top Premarket Gainers

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

GlobeNewswire

2 months ago

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

GlobeNewswire

2 months ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago

Simply Wall St.

2 months ago

Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago

MT Newswires

2 months ago

Correction: Wolfe Initiates Coverage on AnaptysBio With Outperform Rating, $25 Price Target

MT Newswires

2 months ago

Truist Securities Initiates Coverage on AnaptysBio With Outperform Rating, $25 Price Target

Vanda and AnaptysBio link for generalised pustular psoriasis therapy

Pharmaceutical Technology

2 months ago

Vanda and AnaptysBio link for generalised pustular psoriasis therapy

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

GlobeNewswire

2 months ago

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

MT Newswires

2 months ago

Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

GlobeNewswire

2 months ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Zacks

2 months ago

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry

Zacks

3 months ago

How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry

Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a Loser

Barrons.com

3 months ago

Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a Loser

Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?

Zacks

3 months ago

Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

3 months ago

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

3 months ago

Truist Securities Cuts Price Target on AnaptysBio to $20 From $30, Maintains Hold Rating

MT Newswires

4 months ago

UBS Adjusts AnaptysBio Price Target to $18 From $33, Maintains Neutral Rating

AnaptysBio Stock Down as Eczema Study Fails to Meet Goals

Zacks

4 months ago

AnaptysBio Stock Down as Eczema Study Fails to Meet Goals

AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints

Clinical Trials Arena

4 months ago

AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints

MT Newswires

4 months ago

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires

4 months ago

Sector Update: Health Care

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

Benzinga

4 months ago

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

MT Newswires

4 months ago

Top Midday Decliners

MT Newswires

4 months ago

Update: AnaptysBio Shares Plunge After Announcing Phase 2B Trial in Atopic Dermatitis Failed to Meet Endpoints

MT Newswires

4 months ago

Wedbush Cuts Price Target on AnaptysBio to $40 From $42, Maintains Outperform Rating

Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?

Zacks

4 months ago

Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?

MT Newswires

4 months ago

AnaptysBio Says Phase 2B Trial in Atopic Dermatitis Failed to Meet Endpoints

MT Newswires

4 months ago

BTIG Downgrades AnaptysBio to Neutral From Buy

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Zacks

4 months ago

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Simply Wall St.

5 months ago

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

5 months ago

AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?

Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)

Zacks

5 months ago

Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)

AnaptysBio Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

5 months ago

AnaptysBio Third Quarter 2024 Earnings: Beats Expectations

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates

Zacks

5 months ago

AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

5 months ago

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Participation in November and December Investor Conferences

GlobeNewswire

5 months ago

Anaptys Announces Participation in November and December Investor Conferences

MT Newswires

5 months ago

AnaptysBio Shares Fall After Eli Lilly Removes Arthritis Drug Peresolimab From Pipeline

Anaptys Announces Participation in September Investor Conferences

GlobeNewswire

7 months ago

Anaptys Announces Participation in September Investor Conferences

Why AnaptysBio Was Such a Healthy Stock This Week

Motley Fool

7 months ago

Why AnaptysBio Was Such a Healthy Stock This Week

MT Newswires

8 months ago

Truist Adjusts Price Target on AnaptysBio to $30 From $20, Maintains Hold Rating

AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering

Investor's Business Daily

8 months ago

AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering

MT Newswires

8 months ago

AnaptysBio Prices $100 Million Common Stock Offering

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

GlobeNewswire

8 months ago

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Investors in AnaptysBio (NASDAQ:ANAB) have seen respectable returns of 74% over the past year

Simply Wall St.

8 months ago

Investors in AnaptysBio (NASDAQ:ANAB) have seen respectable returns of 74% over the past year

MT Newswires

8 months ago

Wedbush Adjusts Price Target on AnaptysBio to $42 From $34, Maintains Outperform Rating

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates

Zacks

8 months ago

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

8 months ago

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Zacks

8 months ago

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Benzinga

8 months ago

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?

Zacks

8 months ago

Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?

MT Newswires

8 months ago

JPMorgan Upgrades AnaptysBio to Overweight From Neutral, Adjusts Price Target to $69 From $29

Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?

Zacks

9 months ago

Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?

Industry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16%

Simply Wall St.

10 months ago

Industry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16%

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

Zacks

a year ago

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

GlobeNewswire

a year ago

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

GlobeNewswire

a year ago

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

a year ago

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?

Zacks

a year ago

AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?

Actym Therapeutics Appoints Thomas Smart as CEO

PR Newswire

a year ago

Actym Therapeutics Appoints Thomas Smart as CEO

Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

Motley Fool

a year ago

Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.

Zacks

a year ago

Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.

Industry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts

Simply Wall St.

a year ago

Industry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts

What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock

Zacks

a year ago

What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock

Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade

Zacks

a year ago

Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

Zacks

a year ago

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

Zacks

a year ago

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for

Zacks

a year ago

Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

GlobeNewswire

a year ago

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

a year ago

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?

13 Best Short Squeeze Stocks To Buy Now

Insider Monkey

a year ago

13 Best Short Squeeze Stocks To Buy Now

Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?

Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?

Heartland Express (HTLD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

a year ago

Heartland Express (HTLD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

Associated Press Finance

a year ago

Hope Bancorp: Q4 Earnings Snapshot

Preferred Bank (NASDAQ:PFBC) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Preferred Bank (NASDAQ:PFBC) Q4 2023 Earnings Call Transcript

Spirit Airlines Stock Tumbles as JetBlue Warns It Could Walk Away From Merger

Barrons.com

a year ago

Spirit Airlines Stock Tumbles as JetBlue Warns It Could Walk Away From Merger

Glass Lewis Tells Hollysys Shareholders to Reject $1.7 Billion Offer

Bloomberg

a year ago

Glass Lewis Tells Hollysys Shareholders to Reject $1.7 Billion Offer

John B. Sanfilippo & Son, Inc. 2nd Quarter Fiscal Year 2024 Operating Results Conference Call

GlobeNewswire

a year ago

John B. Sanfilippo & Son, Inc. 2nd Quarter Fiscal Year 2024 Operating Results Conference Call

Newsfile

a year ago

IAMGOLD Announces Regulatory Approval in France of Buy-Out Offer for Euro Ressources

Reuters

a year ago

CANADA STOCKS-China hopes help lift Toronto market for fourth day

Reuters

a year ago

CANADA STOCKS-TSX hits one-week high on materials boost; BoC rate decision in focus

Greenbrier Companies (GBX) Just Flashed Golden Cross Signal: Do You Buy?

Zacks

a year ago

Greenbrier Companies (GBX) Just Flashed Golden Cross Signal: Do You Buy?

CrossFirst Bankshares (CFB) Q4 Earnings Surpass Estimates

Zacks

a year ago

CrossFirst Bankshares (CFB) Q4 Earnings Surpass Estimates

GuruFocus.com

a year ago

CrossFirst Bankshares Inc Reports Record Full Year Earnings for 2023

Share on Social Networks: